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A B S T R A C T
Acute pancreatitis (AP) causes morbidity and mortality. The aim of the present study was to investigate
the protective effect of tropisetron against AP induced by cerulein.
Cerulein (50 mg/kg, 5 doses) was used to induce AP in mice. Six hours after ﬁnal cerulein injection,
animals were decapitated. Hepatic/pancreatic enzymes in the serum, pancreatic content of
malondialdehyde (MDA), pro-inﬂammatory cytokines and myeloperoxidase (MPO) activity were
measured.
Tropisetron signiﬁcantly attenuated pancreatic injury markers and decreased the amount of elevated
serum amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), MPO activities
and pro-inﬂammatory cytokines levels caused by AP in mice. Tropisetron didn’t affect the pancreatic
levels of MDA.
Our results suggest that tropisetron could attenuate cerulein-induced AP by combating inﬂammatory
signaling. Further clinical studies are needed to conﬁrm its efﬁcacy in patients with AP.
© 2017 Elsevier Masson SAS. All rights reserved.
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Acute pancreatitis (AP) is an inﬂammatory disorder of the
pancreas and the leading cause of hospitalization among different
types of gastrointestinal disorders worldwide [1]. Epidemiologic
analysis revealed that hospital admissions for AP increased from 40
per 100,000 in 1998 to 70 per 100,000 in 2002 [2]. The molecular
mechanisms underlying AP are not fully understood yet, but it has
been shown that inﬂammatory mediators play an important role in
the progression and severity of AP [3]. Acinar cell injury caused by
factors like gallstones in the distal common bile duct, alcohol abuse
and endoscopic retrograde cholangiopancreatography (ERCP) led
to release of digestive enzymes [4,5]. Subsequent to acinar cell
injury, inﬂammatory cytokines including interleukin 6 (IL-6),
interleukin 8 (IL-8), Tumor necrosis factor alpha (TNF-a) are
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apoptosis in acinar cells and stimulate neutrophils to be recruited
at the site of inﬂammation [7,8]. Furthermore, pancreatic enzymes
could reach distant organs like lung and live through systemic
circulation and cause injury [6]. For example, pancreatic elastase
induced liver inﬂammation and upregulation of hepatic TNF
predominantly within Kupffer cells [9,10]. Also, it was shown that
interleukin-1 and TNF can increase the expression of other
cytokines and related genes, which ﬁnally resulted in systemic
inﬂammatory response to acute pancreatitis and the subsequent
organ failure [6,11].
Current therapies including antisecretory agents, protease
inhibitors, antioxidants, immunomodulators and etc., are insufﬁ-
cient for treatment of this disease. So, there is a pressing need for
more effective therapies [12].
Tropisetron, a 5-HT3 receptor antagonist, is widely used to treat
chemotherapy associated emesis [13]. Anti-inﬂammatory and
antioxidant aspects of tropisetron have been shown in various
peripheral and central inﬂammatory settings [14], including
experimental colitis[15], cisplatin-induced nephrotoxicity [16],
ischemic stroke [17], beta-amyloid-induced neuroinﬂammation
[18] and animal model of multiple sclerosis[19]. Furthermore, in a
rat model of cecal ligation and puncture (CLP)- induced sepsis
tropisetron administration signiﬁcantly inhibited TNF-a and IL-6
overproduction in serum [20]. Although the exact mechanisms
underlying anti-inﬂammatory effects of tropiseton have not been
identiﬁed yet, different canonical pathways involved in inﬂamma-
tion such as Nuclear factor-kB (NF-kB), calcineurin, mitogen-
activated protein kinase (MAPK), peroxisome proliferator-activat-
ed receptor gamma (PPARg) and Alpha7 nicotinic acetylcholine
receptor (a7 nAChR) have been shown as targets of tropisetron
[14].
Regarding the remarkable anti-inﬂammatory properties of
tropisetron and its wide therapeutic window, it would be plausible
to investigate the protective aspects of tropisetron in an
experimental model of AP. In this context the possible protective
actions of tropisetron was studied in cerulein-induced AP in mice.
2. Materials and methods
2.1. Animals
Male NMR mice weighing 25–30 g were randomly assigned to 3
experimental groups (each group contains 6 animals). The animals
were housed for one week before the experiments to acclimatize to
new conditions. The experimental procedures were approved by
the Ethics Committee of Iran University of Medical Sciences,
Tehran, Iran in accordance with the Standards for the Care and Use
of Laboratory Animals. Animals were kept in a room with 12-h
light/12-h dark cycle and 22–24 C.
2.2. Induction of pancreatitis
Acute pancreatitis was induced by cerulein (50 mg/kg, ip,5
doses at hourly intervals) [21]. In treatment group, tropisetron
(2 mg/kg, ip) was administered twice at the intervals of one and six
hours after the ﬁrst cerulein administration. Control group
received normal saline in the same manner.
Six hours after the last cerulein injection, animals were
euthanized, blood samples were collected and pancreases
removed and snap frozen in liquid nitrogen and then kept at
80 C for later biochemical measurements. Blood samples were
used to determine the serum amylase and lipase activities. A
portion of pancreases was ﬁxed in 10% formalin for histopatho-
logical evaluation.2.3. Biochemical analysis
The serum amylase, lipase, aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) activities were determined
using the commercially available kits (Pars-Azmun Co. Tehran,
Iran) [22].
2.4. Determination of lipid peroxidation
Malondialdehyde (MDA) level was measurement as an indica-
tor of lipid peroxidation with thiobarbituric acid (TBA) based
reaction [23]. Brieﬂy, the pancreas tissue was homogenized in
1.15% KCl solution. Then, 0.1 ml of the homogenate was added to a
reaction solution containing 0.2 ml of sodium dodecyl sulfate (SDS)
(8.1%), 1.5 ml of acetic acid (20%), 1.5 ml of TBA (0.8%) and 0.7 ml of
distilled water. Samples were boiled for 30 min at 95 C. TBA-
treated samples were mixed with n-butanol and centrifuged at
3000 g for 10 min. The absorbance of the supernatant was read at
532 nm with a spectrophotometer. MDA level was expressed as
mM/100 g tissue.
2.5. Determination of total myeloperoxidase activity (MPO) activity
MPO activity, an indicator of neutrophil sequestration in the
pancreas, was determined as previously decribed [24]. Concisely,
pancreatic tissues were homogenized in 10 mM potassium
phosphate buffer (pH 7.4) containing 0.5% (w/v) hexadecyl
trimethyl ammonium bromide (50 mg tissue/mL). The homoge-
nates were centrifuged for 30 min at 20,000 g at 4 C. After that, the
supernatant was allowed to react with a solution containing
tetramethyl benzidine (1.6 mM) and hydrogen peroxide (0.1 mM).
The rate of change in absorbance was measured spectrophotomet-
rically at 650 nm. Myeloperoxidase activity was deﬁned as the
quantity of enzyme degrading 1 mmol peroxide/min at 37 C.
Values were expressed as MPO in units/g wet tissue.
2.6. Histopathological examination and scoring
After decapitating of mice, a portion of pancreases was ﬁxed in
10% formalin for 24–48 h. Then, pancreases were embedded in
parafﬁn to be cut into 5 mm-thick sections and dying with
hematoxylin and eosin. Finally, a pathologist observed the tissue
sections under light microscope blindly and scored them (1–4)
through evaluating the following criteria: edema, pro-inﬂamma-
tory cell inﬁltration, acinar vacuolization and necrosis (one is
normal and 4 is severe) [25].
2.7. Determination of inﬂammatory mediators
To determine the inﬂammatory cytokine levels, the pancreatic
tissues were homogenized as described by previously [26]. Brieﬂy,
a lysis buffer was prepared containing 200 mM NaCl, 5 mM EDTA,
10 mM tris, 10% glycerin and 1 mM PMSF. Next, one tablet of
protease inhibitor cocktail was added for 10 ml of lysis buffer.
Finally, the pH was adjusted to 7.4. After that, we added 200 ml lysis
buffer to 10 mg tissue before homogenization. Samples were
centrifuged twice (1500 g at 4 C for 15 min) to avoid contamina-
tion of cell debris. The supernatant was used for measurement of
cytokines. Enzyme-linked immunosorbent assay (ELISA) kits were
used for measurement of TNF-a, Interleukin 1 beta (IL-1b) in the
pancreas samples (duplicate experiments).
2.8. Statistical analysis
Histologic damage score is presented as median  interquartile
range (IQR). For analysis of this factor, Kruskal-Wallis test followed
Fig. 1. Effect of tropisetron (tropi) on pancreatic and hepatic enzymes production after cerulein administration. Cerulein signiﬁcantly increased the activities of lipase (A),
amylase (B), ALT (C) and AST (D). Tropisetron administration (2 mg/kg) in cerulein-injected mice signiﬁcantly diminished the enzymes activity. Each bar represents mean  S.
E.M. # P < 0.05, versus the sham group; * p < 0.05, versus cerulein group. ## and **, p < 0.001 (n = 6 per group).
Fig. 2. Effect of tropisetron (tropi) on pancreatic MPO activity during AP.
Tropisetron treatment reduced the MPO activity. Each bar represents mean  S.E.
M. # P < 0.05, versus the sham group; * p < 0.05, versus cerulein group. ## and **,
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expressed as mean  SEM and statistical differences were analyzed
by one-way ANOVA followed by Tukey post-hoc test. P value < 0.05
was considered signiﬁcant.
3. Results
3.1. Effects of tropisetron on pancreatic and hepatic enzymes
The levels of serum amylase and lipase were increased
following induction of AP by cerulein. It has been shown that
the levels of hepatic enzymes such as AST and ALT increase in
patients with AP [27]. In fact, liver injury was assessed in AP as a
clinical prognostic indicator and it is used to predict the severity of
acute pancreatitis [28].
Similarly, in our study serum levels of AST and ALT were
signiﬁcantly increased in cerulein-treated animals. As depicted in
Fig. 1.A–D, treatment of animals with tropisetron signiﬁcantly
reduced the elevated levels of pancreatic and hepatic enzymes
(p < 0.001).
3.2. Effect of tropisetron on cerulein-induced oxidative stress and
leukocytes inﬁltration
During AP, neutrophils are recruited from the circulation to
pancreases and enhanced the production of reactive oxygen
species (ROS) and pro-inﬂammatory cytokines in response to an
inﬂammatory stimulation [8]. In the present study, pancreatic
MDA levels notably increased in mice treated with cerulein while
tropisetron had no effect on lipid peroxidation caused by cerulein
(data not shown).
MPO activity was measured as an index of neutrophil
inﬁltration. Cerulein signiﬁcantly (p < 0.001) elevated the MPO
activity as an indicator of neutrophil sequestration in the pancreas.This change was reversed by treatment of animals with tropisetron
(2 mg/kg) (Fig. 2). This effect corroborates our pervious ﬁndings
showed that tropisetron diminished MPO activity in inﬂamed
colon via 5-HT3 receptor dependent and non-dependent mecha-
nisms [15].
3.3. Effects of tropisetron on inﬂammatory cytokines
Cerulein administration induces activation of the transcription
factor NF-kB. This effect is accompanied by a notable decrease of
inhibitory protein, Inhibitor kappa B-alpha (IkBa) content.
Therefore, NF-kB activation has a pivotal role in controlling the
inﬂammatory signaling that happens in cerulean-induced AP [29].p < 0.001 (n = 6 per group).
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inﬂammatory cytokines such as TNF-a and IL-1b. These cytokines
increase the recruitment of neutrophils into the pancreas.
Increased levels of inﬂammatory cytokines have been observed
in both acute human and experimental pancreatitis [30,31]. In our
hands cerulein administration enhanced pancreatic levels of TNF-
a and IL-1b by 5-fold compared to saline treated mice. As shown in
Fig. 4, tropisetron signiﬁcantly decreased the levels of TNF-a (p
< 0.001) and IL-1b (p = 0.001) in pancreas tissue (Fig. 3A, B)
indicating its potent anti-inﬂammatory aspects. These results
conﬁrm different experimental ﬁndings revealed tropisetron
administration exerts notable protective effects in peripheral
and central inﬂammatory conditions such as experimental
inﬂammatory bowel disease[15], experimental autoimmune
encephalomyelitis[19], stroke [17] and beta-amyloid-induced
neuroinﬂammation [18]. The protective actions of tropisetron in
AP could be a classical 5-HT3 receptor dependent effects as recently
ondansetron, another 5-HT3 receptor antagonists, was shown to
decrease serum levels of amylase and lipase, cell inﬁltration and
cytokine production in cerulean-induced AP [32].
3.4. Effects of tropisetron on pancreas histological changes associated
with cerulein
Administration of cerulein (50 mg/kg/h, 5, i.p.) resulted in
massive pancreatic injury characterized by leucocytes inﬁltration,
edema and acinar cell necrosis (Fig. 4B); however, co-treatment of
tropisetron and cerulein in mice improved histopathologic
damages compared to cerulein group (Fig. 4C). Fig. 4D presents
histological scoring of pancreatic tissue damage in normal mice
and cerulein-treated mice in presence or absence tropisetron.
Tropisetron reduced histological damages compared to cerulein
group but the effect was not statistically signiﬁcant.
4. Discussion
AP is an inﬂammatory disorder of pancreas which appears to be
rising during last decades and causes a signiﬁcant mortality [2]. Up
to now, a lot of components were investigated to attenuate this
condition but few were effective enough to be used in patients, so
researches continue to ﬁnd safe and effective compounds to treat
AP [33].
We showed for the ﬁrst time that tropisetron (2 mg/kg)
diminished cerulein-induced AP. Induction of pancreatitis by
cerulein is a well-established model of AP and mimics histopatho-
logical characteristic of human pancreatitis [3]. In both animal and
clinical studies, levels of liver and pancreatic enzymes increased in
AP [1,21]. In this study, IP injection of cerulean caused elevation ofFig. 3. Effect of tropisetron (tropi) on pancreatic TNF-a (A) and IL-1b (B) content 
inﬂammatory mediators. Each bar represents mean  S.E.M. # P < 0.05, versus the shamthese enzymes and administration of tropisetron (2 mg/kg)
resulted in signiﬁcant reduction of pancreatic enzymes activities.
It has been demonstrated that pancreatic enzymes could access
the systemic circulation as the result of inﬂammatory changes in
the pancreas and retroperitoneum. They cause damage to distant
organs such as the liver through producing the inﬂammatory
mediators [28]. In this context, cerulein administration led to liver
injury shown by the increase in AST and ALT while tropisetron
signiﬁcantly decreased cerulein associated increase of hepatic
enzymes such as ALT and AST. MPO activity is an indicator of
neutrophils which recruits into pancreas [8]. At the early stage of
AP, damage to the pancreatic cell leads to the release of
inﬂammatory cytokines which cause inﬁltration of neutrophils
into the pancreas. The activated neutrophils release a huge amount
of oxidants and cytotoxic agents which further exacerbates the
local damage to the pancreatic tissues. In the present study, we
observed that the administration of tropisetron alleviated the
cerulein-induced pancreatic MPO activity. This effect is similar to
those we observed in the experimental model of IBD [34].
Furthermore, an earlier study showed that pro-inﬂammatory
cytokines play a critical role in AP, probably via inducing
deleterious leukocyte accumulation within the pancreas [29].
These inﬂammatory cytokines have been reported to be involved in
the pathogenesis of AP. Tropisetron signiﬁcantly inhibited cer-
ulein-induced inﬂammatory cytokines including TNF-a and IL-1b
production.
The ﬁndings of the present study conﬁrmed our previous
ﬁndings that tropisetron had anti-inﬂammatory aspects in
different inﬂammatory context [15]. Tropisetron notably de-
creased renal injury and content of pro-inﬂammatory cytokines
in mice treated with cisplatin [16]. It has been shown that
tropisetron could inhibit IL-1b/TNFa release through preventing
the phosphorylation and activation of the p38 MAPK in human
primary monocytes [35]. This protein is involved in post-
transcriptional regulation of the inﬂammatory cytokines [36]
and its activity has been shown to increase dose-dependently
following a single injection of cerulein in pancreatic tissue [37]. Liu
et al. demonstrated that tropisetron (1 or 3 mg/kg) can diminish
inﬂammatory cell responses and organ damage caused by trauma-
hemorrhage [38]. In contrast with the previous study, they
reported that the protective effect of tropisetron was reversed
by co-administration of the p38 MAPK inhibitor (SB-203580) after
trauma-hemorrhage. They concluded the salutary effects of
tropisetron are mediated through p38 MAPK-dependent HO-1
expression [38]. Apparently, results of the two mentioned study
are in opposite of each other but it has been proved that p38 MAPK
pathway is involved both anti-inﬂammatory and pro-inﬂammato-
ry processes [39]. P38 pathway controls the expression ofafter cerulein administration. Tropisetron (2 mg/kg) inhibited the production of
 group; * p < 0.05, versus cerulein group. ## and **, p < 0.001 (n = 6 per group).
Fig. 4. Effect of tropisetron on histological changes induced by cerulein.
A) Section from mice pancreas with normal histopathologic features. B)
Section from pancreas of cerulein-treated mice showing severe edema, inﬂamma-
tory cell inﬁltration and focal necrosis. C), Section from mice treated with cerulein
and tropisetron shows mild leucocytes inﬁltration without tissue necrosis.
Hematoxylin & Eosin (H&E) staining was used, 400. Tropisetron improved
damage scores in comparison to cerulein-treated mice (D). Data of histopathologic
score are reported as medians IQR. # P < 0.05, versus the sham group; * p < 0.05,
versus cerulein group. (n = 6 per group).
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well as pro-inﬂammatory cytokines [40]. Collectively, it seems that
tropisetron blocks p38 MAPK for a short time because it has been
suggested that long-term blockade of the pathway has limited
anti-inﬂammatory effect [40].
Epigastric or left upper quadrant pain is an early symptom of AP
and usually, patients with AP suffer from severe pain whichradiates to the back, chest, or ﬂanks [2,41]. Analgesic aspects of
tropisetron could attenuate AP associate complications such as
pain. Interestingly both experimental and clinical studies suggest
that 5-HT3 receptor antagonists are effective in chronic pain
reduction, especially in situations associated with inﬂammatory
origin. Okamoto et al. have shown that systemic and local
administrations of tropisetron produce antinociceptive effects,
mainly in the late phase in the animal model of formalin test [42].
In a randomized clinical trial, Mei et al. reported that a single-dose
intravenous administration of tropisetron signiﬁcantly alleviates
early postoperative pain in women undergoing gynecological
laparoscopies compared with those receiving placebo [43].
Likewise, Intrathecal administration of tropisetron in rats with
spinal cord injury, decreased hyperalgesia and mechanical
allodynia [44].
High blood glucose is found in patients with AP, especially in
those with necrotizing pancreatitis [45]. Moreover, the ﬁndings of
a recent meta-analysis indicated that patients with AP form almost
40% of newly diagnosed prediabetes or diabetes mellitus (DM)
after discharge from the hospital, and it doubles the risk of DM over
5 years [46]. Interestingly, both in vivo and in vitro studies indicate
that tropisetron has therapeutic potential to be control high blood
glucose levels. [47]. It has been shown that administration of
ondansetron, a 5-HT3 receptor antagonist, reduced elevated level
of blood glucose in stressed rats stimulated by meta-chlorophe-
nylbiguanide (m-CPBG) [48]. Another report indicated that
tropisetron is able to enhance the insulin release in the beta-cell
line (INS-1) [49], especially in presence of serotonin. Serotonin
reduced the glucose-stimulated release of insulin in a concentra-
tion-dependent manner, while tropisetron abolished this inhibi-
tion. It shows the involvement of 5-HT3 receptors in tropisetron-
induced insulin secretion [49]. The exact mechanism concerning
secretagogue action of 5-HT3 antagonists is still unknown to a large
extent. However, classical insulin secreting agents (sulfonylureas)
block KATP channels causes depolarization, Ca2+ entry and insulin
secretion but 5-HT3 antagonists reduce cation inﬂux, in particular
Ca2+. Furthermore, no hypoglycemic effect has been reported with
therapeutic doses of 5-HT3 receptor antagonists [13,50]. Fascinat-
ingly, cytosolic calcium concentration regulates protease activa-
tion in acinar cells and also calcineurin, a Ca2+-calmodulin
dependent serine/threonine protein phosphatase, which is critical
for numerous cellular processes and calcium-dependent signal
transduction pathways [51,52]. Nuclear factor of activated T cells
(NFAT) transcription factor is an important downstream target of
calcineurin [53].
it has been shown that pharmacologic inhibition of NFAT
signaling resulted in reduction of AP-induced activation of
trypsinogen, systemic inﬂammation and tissue damage, as well
as neutrophil recruitment in the pancreas [52]. In in vivo model, we
and others showed that 5-HT3 receptor antagonist, tropisetron has
anti-inﬂammatory effects by inhibiting calcineurin/NFAT signaling
pathway in neurons, lymphocytes and myocardiocytes [54–56].
5. Conclusion
Several 5-HT3 receptor dependent and non-dependent mecha-
nisms might contribute to the beneﬁcial effects with tropisetroni
in experimental AP; I; inhibition of the p38 MAPK, which is
involved in the post-transcriptional regulation of different
cytokines such as TNF-a and IL-1b [35]. II; Tropisetron bears an
electron rich indole ring in its structure and serves as an electron
donor, thereby, it has notable antioxidant properties [13,57]. III;
Tropisetron is the partial agonist of a7 nAChR which could regulate
immune cells activity like macrophages via inhibition of NF-kB
nuclear translocation [58–60]. It has been clearly shown that
increased NF-kB activity lead to rise in the cytokine gene
594 R. Rahimian et al. / Biomedicine & Pharmacotherapy 93 (2017) 589–595expression, leukocyte inﬁltration, and inﬂammation which play a
pivotal role in initiation and severity of AP [61]. IV; Tropisetron
could increase PPARg activity and consequently activate anti-
inﬂammatory pathways downstream of PPARg [38].
In conclusion, our ﬁndings suggest that tropisetron has the
potential to be used for the treatment of AP; however, further
clinical investigations are required to conﬁrm its safety and
efﬁcacy.
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